Selection of Cytochrome P450 Genes for Use in Prodrug Activation-Based Cancer Gene Therapy
Prodrug activation-based cancer gene therapy is a molecular strategy to improve the efficacy of cancer chemotherapy by conferring upon tumor cells the capability to metabolize specific anticancer prodrugs into lethal intracellular toxins. The overall goal of this strategy is to increase the generation of cytotoxic drug metabolites locally, at their site of action within the tumor. This therapy can provide for an increase in drug efficacy and potentially also a reduction in host toxicity, which may be achieved by a lowering of the therapeutically effective drug dosage, thereby reducing the need to expose host tissues to high cytotoxic plasma drug concentrations. This chapter describes the cytochrome P450-based prodrug activation strategy for cancer gene therapy , with a particular emphasis on the selection of suitable P450 gene/prodrug combinations.
- Rescue and Isolation of Rb-deficient Prostate Epithelium by Tissue Recombination
- Genetic Alterations in Esophageal Cancer
- Other Lymphoid Malignancies: Cytogenetic Techniques
- Direction of the Recognition Specificity of Cytotoxic T Cells Toward Tumor Cells by Transduced, Chimeric T-Cell Receptor Genes
- Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms
- Enhancer Trap Method Using a Green Fluorescent Protein Reporter Plasmid for Cloning Tissue-Specific Enhancers Active in Prostate
- Detecting and Modulating the NF-kB Activity in Human Immune Cells: Generation of Human Cell Lines with Altered Levels of NF-B
- 钙离子浓度变化数据的处理
- 稳定转染:从G418浓度确定到单克隆化鉴定
- 单克隆抗体制备-液体石蜡的处理